Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
31 May 2019 | Story Eugene Seegers | Photo Barend Nagel
KovsieApp Landing Page
The new KovsieApp’s landing page.

The new KovsieApp will be available from 31 May 2019. This mobile app will be compatible with both iPhone and Android devices and will enable users to access information from the UFS website on their mobile phones at no cost while connected to the on-campus Wi-Fi network.

The first roll-out of the KovsieApp will be primarily aimed at students, who will be able to access their personal information, such as study records, marks, class and exam timetables, mini fee statement, etc. However, for security reasons and privacy requirements, the student will have to register on the app before such information is made available. Later iterations will have additional functionality for staff, for whom space has already been allocated in the app.

Positive Response

During the beta testing phase, a number of students were included in the focus group. Their feedback highlights the value of the app for Kovsie students.

“The app is very smooth and easy to use. Compared to other apps, it has so much more useful information that a student needs, such as checking Gradebook or your financial statement wherever you are. One of the key aspects is that it is data-friendly, even when on mobile data,” said Omar-Raphael Tabengwa, SRC: International Student Council, in his response.

Katleho Lechoo, SRC for Sport on the Bloemfontein Campus, said: “This app is something the students have been looking for, and it brings the university to your pocket. It is convenient to use, especially for those who have to access their academics while travelling for sport. We can’t wait for it to hit the ground running very fast.”

Nomathemba Pakade, Deputy President of the South Campus SRC, had this to say: “For me, this app means convenience and it is going to save me a lot of time, because I can access almost everything on my phone. We couldn't have asked for anything better at this moment.”

Lastly, Mvuyo Madlala, SRC Secretary for the South Campus, said, “The KovsieApp is very efficient and includes all the essential information that a student might require.”

Data accuracy a must

Since students will log in with an OTP sent to the cellphone number linked to their profile, the accuracy of a student’s data will be critical to the correct functioning of the KovsieApp, especially when it comes to personalised information such as timetables and marks. Therefore, students are encouraged to update their contact details and other information, using the Student Self-service page on KovsieLife. Alternatively, you can visit Student Academic Services for assistance (remember to take along your ID or passport as identification). Any errors in a student’s data can cause the KovsieApp to function unpredictably, with the result that the person will be restricted to a public view with limited access to basic personal information.

The future is here!

Get ready to experience the next generation of information access: Download your KovsieApp today!

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept